# Takeda Pharmaceutical

Type: Company (TAK)

Source: GetYourBrief — https://getyourbrief.com/entity/takeda-pharmaceutical
Canonical HTML page: https://getyourbrief.com/entity/takeda-pharmaceutical

## Timeline

- **2031**: Market Peak — Projected valuation of $25.15 billion reached through global capacity expansion.
- **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
- **2026**: Current Milestone — Market valuation hits significant mid-term growth targets as supply meets latent demand.
- **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
- **2024-01-31**: Takeda Partnership — Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
- **2024**: Infrastructure Investment — Major fractionators announce multi-billion dollar investments in automated collection centers.
- **2022**: Supply Recovery — Plasma collection volumes begin to stabilize following pandemic-era disruptions.

## Recent coverage (3 stories, network-wide)

### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones
2026-03-17 07:33:39 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026

### Immunoglobulin Market to Hit $25.15B by 2031 as Plasma Supply Surges
2026-02-20 13:56:12 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
Full story: https://getbiobrief.com/story/immunoglobulin-market-growth-2031-plasma-collection

### Immunoglobulin Market Set for $25.15B Valuation by 2031 Amid Plasma Surge
2026-02-20 13:51:17 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.
Full story: https://gethealthbrief.com/story/immunoglobulin-market-growth-2031-plasma-expansion

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.